23andMe eyes Big Pharma for future growth

Mountain View, CA-based 23andMe is moving beyond its roots as a provider of consumer genetic tests, reports Xconomy's Luke Timmerman. The company has been targeting a new customer base, drug companies, which can tap the firm's database of 75,000 people for research purposes. "We still give people access to their genetic information," 23andMe CEO Anne Wojcicki said during a May 15 talk at a conference in Seattle. "But a lot more than that, we are really a research company." Story

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.